168830-93-1

Basic information

• Product Name: TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE
• Synonyms: TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE;(4-Bromomethyl-phenyl)-methyl-carbamic acid tert-butyl ester
• CAS NO: 168830-93-1
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.194
• Mol File: 168830-93-1.mol

Chemical Properties

• Boiling Point: 357.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.325±0.06 g/cm3(Predicted)
• PKA: -0.19±0.50(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE(168830-93-1)
• EPA Substance Registry System: TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE(168830-93-1)

Safety Data

• Hazardous Substances Data: 168830-93-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE is used as an intermediate in the synthesis of potential drug candidates. Its unique structure and reactivity make it a valuable component in the development of new pharmaceuticals.
Used in Agrochemical Production:
This chemical compound is also utilized in the production of agrochemicals, where it serves as a key intermediate for the synthesis of various agricultural chemicals that help in crop protection and enhancement of yield.
Used in Specialty Chemicals Industry:
TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE finds applications in the specialty chemicals industry, where it is employed in the synthesis of specific compounds used in various industrial applications.
Safety Considerations:
Due to its potential health and environmental hazards, TERT-BUTYL 4-(BROMOMETHYL)PHENYL(METHYL)CARBAMATE is handled and used with caution. Proper safety measures and handling protocols are essential to minimize risks associated with its use.

Upstream product

• 693803-44-0 tert-butyl N-p-tolyl-N-methylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 623-08-5 N-methyl-p-toluidine 
• 172353-84-3 tert-butyl((4-hydroxymethyl)phenyl)(methyl)carbamate 
• 10541-83-0 N-methyl-p-aminobenzoic acid 
• 263021-30-3 4-((tert-butoxycarbonyl)(methyl)amino)benzoic acid 

Downstream Products

• 168830-88-4 [4-(4-benzhydrylcarbamoyloxy-piperidin-1-ylmethyl)-phenyl]-methyl-carbamic acid tert-butyl ester 
• 442910-11-4 C₂₁H₂₃N₇O₃ 
• 442909-23-1 7-(2-furyl)-3-(4-(N-methylamino)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 
• 168830-70-4 benzhydryl-carbamic acid 1-(4-methylamino-benzyl)-piperidin-4-yl ester 

Relevant articles and documents

Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms associated with Parkinson's disease. This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine. We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivatives that display functional antagonism of the A2A receptor. Optimization of these compounds has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivatives. These efforts have led to the discovery of 60 (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease. Furthermore, this derivative has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies. This compound is presently undergoing further clinical evaluation in collaboration with Biogen Idec.

PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES

The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

Selective muscarinic antagonists. I. Synthesis and antimuscarinic properties of 4-piperidyl benzhydrylcarbamate derivatives

A series of 1-substituted-4-piperidyl benzhydrylcarbamate derivatives were synthesized and evaluated for binding affinity to M1, M2 and M3 receptors, and for antimuscarinic activities. Receptor binding assays indicated that 1-benzyl-4-piperidyl benzhydrylcarbamate derivatives showed higher affinities for M1 and M3 receptors, and good selectivities for M3 over M2 receptor, than the corresponding ester analog. These results indicate that the urethane bond is a novel linker for muscarinic antagonists, and serves to lock the molecular conformation and allows the hydrophobic portion and cationic site of the molecule to bind to M1 and M3 muscarinic receptors. Among the prepared compounds, 1-(4-methylaminobenzyl)-4-piperidyl benzhydrylcarbamate monohydrochloride (18b, YM-58790) exhibited potent inhibitory activity on bladder pressure in reflexly-evoked rhythmic contraction, comparable to oxybutynin and was approximately ten times less inhibitory on oxotremorine-induced salivary secretion than oxybutynin in rats. Further evaluation of antimuscarinic effects on bradycardia and pressor in pithed rats, and on tremor in mice, demonstrated that YM-58790 can be useful for treatment of urinary urge incontinence as a bladder-selective M3 antagonist with fewer side effects.